Organogenesis (NASDAQ:ORGO) Shares Gap Up to $3.44

Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $3.44, but opened at $3.96. Organogenesis shares last traded at $3.98, with a volume of 960,343 shares trading hands.

Analyst Ratings Changes

Separately, BTIG Research upgraded Organogenesis from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Tuesday.

Organogenesis Trading Down 4.5 %

The business has a 50 day simple moving average of $2.32 and a two-hundred day simple moving average of $2.52. The company has a current ratio of 2.85, a quick ratio of 2.51 and a debt-to-equity ratio of 0.25. The stock has a market cap of $500.10 million, a price-to-earnings ratio of 34.64 and a beta of 1.52.

Organogenesis (NASDAQ:ORGO – Get Rating) last issued its earnings results on Wednesday, March 1st. The company reported $0.06 EPS for the quarter. The company had revenue of $115.52 million during the quarter. Organogenesis had a return on equity of 8.03% and a net margin of 2.92%.

Insider Transactions at Organogenesis

In other news, major shareholder Albert Erani sold 25,000 shares of Organogenesis stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $2.07, for a total value of $51,750.00. Following the completion of the transaction, the insider now owns 59,223,027 shares in the company, valued at approximately $122,591,665.89. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 34.40% of the company’s stock.

Institutional Trading of Organogenesis

Several hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can lifted its holdings in shares of Organogenesis by 8.7% in the 1st quarter. Bank of Montreal Can now owns 21,517 shares of the company’s stock worth $165,000 after purchasing an additional 1,721 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Organogenesis by 80.1% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after purchasing an additional 2,396 shares during the last quarter. Yousif Capital Management LLC lifted its holdings in shares of Organogenesis by 3.5% in the 1st quarter. Yousif Capital Management LLC now owns 74,492 shares of the company’s stock worth $568,000 after purchasing an additional 2,495 shares during the last quarter. Credit Suisse AG lifted its holdings in shares of Organogenesis by 3.7% in the 2nd quarter. Credit Suisse AG now owns 92,961 shares of the company’s stock worth $454,000 after purchasing an additional 3,330 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its holdings in shares of Organogenesis by 32.3% in the 3rd quarter. Mutual of America Capital Management LLC now owns 14,060 shares of the company’s stock worth $46,000 after purchasing an additional 3,433 shares during the last quarter. Institutional investors own 47.03% of the company’s stock.

About Organogenesis

(Get Rating)

Organogenesis Holdings, Inc is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.